Faculty

Maciej M. Mrugala, M.D., Ph.D.

Clinical Studies

A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study To Evaluate The Safety, Tolerability And Antitumor Activity Of TX103 CAR-T Cell Injection (TX103) In Subjects With Recurrent Or Progressive Grade 4 Glioma. Scottsdale/Phoenix, AZ Rochester, MN
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study To Evaluate The Safety, Tolerability And Antitumor Activity Of TX103 CAR-T Cell Injection (TX103) In Subjects With Recurrent Or Progressive Grade 4 Glioma. Jacksonville, FL
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Brain Tumor Repository Scottsdale/Phoenix, AZ
The main objective of the Brain Tumor Repository is to allow access to coded patient data by researchers both inside and outside of the Mayo Clinic system so that important research questions can be answered.
Phase I/II Combination Study Of NMS-03305293 And Temozolomide In Adult Patients With Recurrent Glioblastoma Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN
The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with temozolomide (TMZ) in patients with diffuse gliomas at first relapse (Phase I), and to determine the antitumor effectiveness of the combination of NMS-03305293 and TMZ in patients with isocitrate dehydrogenase (IDH) wild type glioblastoma at first relapse as measured by the 6-month Progression Free Survival (PFS) rate (Phase II).